Potensi Aktivitas Buah Sawit (Elaeis guineensis)  Terhadap Kanker Tulang Dengan Metode Docking melului ikatan dengan MCF1R

Samsul Hadi; Nanda Hesti  Rahmawati; Erika indriani

doi:10.58794/jfarm.v3i1.1278

Authors

Samsul Hadi Unversitas Lambung Mangkurat
Nanda Hesti Rahmawati Universitas Lambung Mangkurat
Erika indriani Universitas Lambung Mangkurat

DOI:

https://doi.org/10.58794/jfarm.v3i1.1278

Keywords:

osteosarcoma, docking, Elaeis guineensis

Abstract

Osteosarkoma adalah kanker tulang agresif dengan tingkat mortalitas tinggi, yang sering menyerang anak-anak dan remaja. Meskipun terapi konvensional telah tersedia, efektivitasnya masih rendah dan memiliki efek samping signifikan. Penelitian ini bertujuan untuk mengevaluasi potensi senyawa bioaktif dari buah sawit (Elaeis guineensis) terhadap osteosarkoma melalui metode docking molekuler. Metodologi penelitian ini menggunakan Macrophage Colony-Stimulating Factor 1 Receptor (MCF1R) sebagai target dokcing dan dipreparasi menggunakan perangkat lunak YASARA, sementara interaksi ligan diuji dengan PLANTS dan divisualisasikan menggunakan PyMOL serta Discovery Studio. Hasil docking menunjukkan bahwa alpha-Tocopherol dan alpha-Tocotrienol memiliki skor afinitas tinggi, masing-masing sebesar -97,0793 dan -98,8046, serta membentuk interaksi kuat dengan residu penting pada MCF1R. Senyawa ini berpotensi menghambat aktivitas MCF1R yang berperan dalam perkembangan osteosarkoma melalui mekanisme interaksi hidrogen dan hidrofobik. Keseimpulan penelitian ini adalah buah sawit berpotensi dikembangkan sebagai agen terapi alternatif osteosarkoma.

References

X. Zhou, J. Wu, C. Duan, and Y. Liu, “Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma.,” J. Immunol. Res., vol. 2020, p. 7890985, 2020, doi: 10.1155/2020/7890985.

J. Shi, M. Li, and R. Yang, “Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy.,” Immunotherapy, vol. 12, no. 9, pp. 641–652, Jun. 2020, doi: 10.2217/imt-2020-0107.

S. P. D’Angelo et al., “Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma.,” Nat. Commun., vol. 13, no. 1, p. 3477, Jun. 2022, doi: 10.1038/s41467-022-30874-8.

A. Le Cesne et al., “Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.,” Eur. J. Cancer, vol. 119, pp. 151–157, Sep. 2019, doi: 10.1016/j.ejca.2019.07.018.

H. A. Tawbi et al., “Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.,” Lancet. Oncol., vol. 18, no. 11, pp. 1493–1501, Nov. 2017, doi: 10.1016/S1470-2045(17)30624-1.

W.-K. Tow, A. P.-T. Goh, U. Sundralingam, U. D. Palanisamy, and Y. Sivasothy, “Flavonoid Composition and Pharmacological Properties of Elaeis guineensis Jacq. Leaf Extracts: A Systematic Review.,” Pharmaceuticals (Basel)., vol. 14, no. 10, Sep. 2021, doi: 10.3390/ph14100961.

S. Abdullah, K. Chong, and S. Ng, “Phytochemical Constituents From Leaves of Elaies Guineensis and Their Antioxidants and Antimicrobial Activities,” Int. J. Pharm. Pharm. Sci., vol. 5, pp. 137–140, Dec. 2013.

R. Varatharajan, M. Z. A. Sattar, I. Chung, M. A. Abdulla, N. M. Kassim, and N. A. Abdullah, “Antioxidant and pro-oxidant effects of oil palm (Elaeis guineensis) leaves extract in experimental diabetic nephropathy: a duration-dependent outcome,” BMC Complement. Altern. Med., vol. 13, no. 1, p. 242, 2013, doi: 10.1186/1472-6882-13-242.

I. S. Ermiş, E. Deveci, and F. Aşır, “NF-ĸB expression in endometriosis induced rat uterine tissue,” J. Drug Deliv. Ther., vol. 13, pp. 33–36, Apr. 2023, doi: 10.22270/jddt.v13i4.6011.

P. Rinthong, P. Pulbutr, and C. Mudjupa, “Molecular docking studies of Triphala with catalytic portion of HMG-CoA reductase enzyme,” J. Herbmed Pharmacol., vol. 12, pp. 262–270, Mar. 2023, doi: 10.34172/jhp.2023.28.

S. Nur, M. Hanafi, H. Setiawan, N. Nursamsiar, and B. Elya, “Molecular Docking Simulation of Reported Phytochemical Compounds from Curculigo latifolia Extract on Target Proteins Related to Skin Antiaging,” Trop. J. Nat. Prod. Res., vol. 7, no. 11, pp. 5067–5080, Dec. 2023.

K. Das et al., “In silico studies and evaluation of in vitro antidiabetic activity of berberine from ethanol seed extract of Coscinium fenestratum (Gaertn.) Colebr,” J. King Saud Univ. - Sci., vol. 35, p. 102666, Apr. 2023, doi: 10.1016/j.jksus.2023.102666.

C. Jenkinson, A. Podgorny, C. Zhong, and B. Oakley, “Computer-Aided, Resistance Gene-Guided Genome Mining for Proteasome and HMG-CoA Reductase Inhibitors,” J. Ind. Microbiol. Biotechnol., vol. 50, Dec. 2023, doi: 10.1093/jimb/kuad045.

P. Pilavaki, M. Panagi, S. Arifi, R. L. Jones, T. Stylianopoulos, and A. Constantinidou, “Exploring the landscape of immunotherapy approaches in sarcomas.,” Front. Oncol., vol. 12, p. 1069963, 2022, doi: 10.3389/fonc.2022.1069963.

O. Clemente et al., “Is immunotherapy in the future of therapeutic management of sarcomas?,” J. Transl. Med., vol. 19, no. 1, p. 173, Apr. 2021, doi: 10.1186/s12967-021-02829-y.

C. Chen, L. Xie, T. Ren, Y. Huang, J. Xu, and W. Guo, “Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.,” Cancer Lett., vol. 500, pp. 1–10, Mar. 2021, doi: 10.1016/j.canlet.2020.12.024.

M. F. Wedekind, L. M. Wagner, and T. P. Cripe, “Immunotherapy for osteosarcoma: Where do we go from here?,” Pediatr. Blood Cancer, vol. 65, no. 9, p. e27227, Sep. 2018, doi: 10.1002/pbc.27227.

R. J. Motzer et al., “Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.,” N. Engl. J. Med., vol. 378, no. 14, pp. 1277–1290, Apr. 2018, doi: 10.1056/NEJMoa1712126.

T. S. K. Mok et al., “Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.,” Lancet (London, England), vol. 393, no. 10183, pp. 1819–1830, May 2019, doi: 10.1016/S0140-6736(18)32409-7.

F. S. Hodi et al., “Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.,” Lancet. Oncol., vol. 19, no. 11, pp. 1480–1492, Nov. 2018, doi: 10.1016/S1470-2045(18)30700-9.

E. Palmerini et al., “Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?,” Pediatr. Blood Cancer, vol. 66, no. 8, p. e27792, Aug. 2019, doi: 10.1002/pbc.27792.

S. S. Bielack et al., “Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Respon,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 33, no. 20, pp. 2279–2287, Jul. 2015, doi: 10.1200/JCO.2014.60.0734.

A. Luetke, P. A. Meyers, I. Lewis, and H. Juergens, “Osteosarcoma treatment - where do we stand? A state of the art review.,” Cancer Treat. Rev., vol. 40, no. 4, pp. 523–532, May 2014, doi: 10.1016/j.ctrv.2013.11.006.